Ovarian Cancer Clinical Trial
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Must have pancreatic, ovarian, gastric, non-small cell cancer or mesothelioma. For dose expansion, must have tumor that is positive for mesothelin
Expected to have life expectancy of at least 3 months
Men and women 18 years old or older (or local age of majority)
Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma
ECOG of 0 to 1
Exclusion Criteria:
Cancer metastases in the brain
Moderate eye disorders
Active infection or past hepatitis B or C infection
Major surgery less than 1 month before the start of the study
Uncontrolled heart disease
Impaired liver or bone marrow function
History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
La Jolla California, 92093, United States
Durham North Carolina, 27710, United States
Liverpool New South Wales, 2170, Australia
Adelaide South Australia, 5000, Australia
Clayton Victoria, 3168, Australia
Nedlands Western Australia, 6009, Australia
Gent Oost-Vlaanderen, 9000, Belgium
Bruxelles , 1200, Belgium
Edmonton Alberta, T6G 1, Canada
Toronto Ontario, M5G 1, Canada
Milan Lombardia, 20141, Italy
Milano , 20133, Italy
Rozzano (milano) , 20089, Italy
Amsterdam , 1066 , Netherlands
Rotterdam , 3015 , Netherlands
Southampton Hampshire, SO16 , United Kingdom
Glasgow Lanarkshire, G12 0, United Kingdom
How clear is this clinincal trial information?
